Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.

Amit Khanal1, Nibash Budhathoki2, Vijay Pal Singh3

  • 1Section of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A.

Anticancer Research
|April 5, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioactive Hydrogels with D-Amino Acid RGD Mimics: A Therapeutic Strategy for Expeditious Infected Wound Closure.

Advanced healthcare materials·2026
Same author

Functional Outcomes of Hip Fracture Surgery in Elderly Patients at a Tertiary Care Hospital in a Rural Area of North India.

Cureus·2026
Same author

Building a humane scientific future: Second Asia Laboratory Animal Day.

Animal models and experimental medicine·2026
Same author

Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.

Medicine·2025
Same author

Observation of Shapiro steps in an ultracold atomic Josephson junction.

Science (New York, N.Y.)·2025
Same author

Shapiro steps in strongly-interacting Fermi gases.

Science (New York, N.Y.)·2025
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

Adult bladder cancer survivors face a significantly higher risk of developing second primary malignancies (SPMs) compared to the general population. Lifelong monitoring is recommended for early detection of these secondary cancers.

Area of Science:

  • Oncology
  • Cancer Epidemiology
  • Public Health

Background:

  • Second primary malignancies (SPMs) are a significant long-term concern for cancer survivors.
  • Bladder cancer survivors are at risk for developing subsequent cancers.

Purpose of the Study:

  • To assess the risk of SPMs in adult patients diagnosed with bladder cancer.
  • To compare SPM incidence in bladder cancer patients to the general population.

Main Methods:

  • Utilized the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) 13 database.
  • Included adult patients (≥18 years) diagnosed with bladder cancer.
  • Calculated SPM risk using SEER*stat software (MP-SIR).

Main Results:

Keywords:
Bladder cancerSEERlatencysecond primary malignancy

Related Experiment Videos

  • Analyzed 103,516 bladder cancer cases; 16.4% developed 19,318 SPMs.
  • Bladder cancer patients showed a 1.42 times higher risk of SPMs (O/E ratio) versus the general population (p<0.001).
  • Common SPMs included prostate, lung/bronchial, and urinary bladder cancers.

Conclusions:

  • Adult bladder cancer patients have a significantly elevated risk for developing SPMs.
  • Long-term surveillance is crucial for bladder cancer survivors to monitor for SPM development.